HIV vaccine testing in South Africa fails

UNITED STATES (OBSERVATORY NEWS) — US health authorities said Monday they would stop testing an experimental vaccine in South Africa against the HIV virus after it was realized it had failed.

The study, named HVTN 702, began in 2016 and included the only vaccine that showed little protection against the AIDS-causing virus.

“The HIV vaccine is essential to end the global pandemic and we have hoped this vaccine will work,” said Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases.

“Unfortunately, it has not worked,” he added.

Part of the test was 5,400 volunteers who tested negative for HIV in 14 areas of South Africa, aged 18 to 35 years.

Based on data from participants over 18 months of testing, it was found that 129 people were affected by the virus while receiving the vaccine, so testing was stopped.

A number of other tests are currently underway to find the vaccine for this virus.

South Africa is one of the highest HIV-infected countries in the world.

According to the United Nations Agency for HIV data, more than 20 percent of the population aged 15-49 in South Africa lives with HIV, while 240,000 people are affected by the virus in 2018./REL


This article is written and prepared by our foreign editors writing for OBSERVATORY NEWS from different countries around the world – material edited and published by OBSERVATORY staff in our newsroom.

Our Standards, Terms of Use: Standard Terms And Conditions.


Contact us: [email protected]

Stay connected with Observatory and Observatory Newsroom, also with our online services and never lost the breaking news stories happening around the world.

Support The OBSERVATORY from as little as $1 – it only takes a minute. Thank you.

We are OBSERVATORY — the only funding and support we get from people – we are categorically not funded by any political party, any government somewhere or from any grouping that supports certain interests – the only support that makes OBSERVATORY possible came from you.